# Immunogenicity, Safety, and Efficacy of Zarzio®/Filgrastim HEXAL® in Patients With Severe Chronic Neutropenia

> **NCT01859637** · PHASE4 · TERMINATED · sponsor: **Sandoz** · enrollment: 6 (actual)

## Conditions studied

- Severe Chronic Neutropenia

## Interventions

- **BIOLOGICAL:** Filgrastim

## Key facts

- **NCT ID:** NCT01859637
- **Lead sponsor:** Sandoz
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-07
- **Primary completion:** 2014-03
- **Final completion:** 2015-09
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Additional pharmacovigilance activity was considered as fulfilled by the EMA.
- **Last updated:** 2016-03-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01859637

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01859637, "Immunogenicity, Safety, and Efficacy of Zarzio®/Filgrastim HEXAL® in Patients With Severe Chronic Neutropenia". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01859637. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*